Expand ACAD Menu
ACAD MENU

ACAD Stock Posts


ACAD #AcadiaPharmaceuticals stock declines -4.3% in after hours trading. See the latest news.

After Hours Decliner

ACAD Acadia Pharmaceuticals26.13+1.00+4.0%

After Hours:25.01-1.12 (-4.3%)

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

Business WireMon, 2-Feb 4:05 PM

ACAD #AcadiaPharmaceuticals stock declines -4.3% in after hours trading. See the latest news.

After Hours Decliner

ACAD Acadia Pharmaceuticals26.13+1.00+4.0%

After Hours:25.01-1.12 (-4.3%)

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

Business WireMon, 2-Feb 4:05 PM

Unusual Option Volume

ACAD Acadia Pharmaceuticals24.50+0.60 (+2.5%)

Acadia Pharmaceuticals trades 2,679 contracts. The company has the following event: Citi's 2025 Global Healthcare Conference on Dec 2, 2025.
Upcoming Earnings

ACAD Acadia Pharmaceuticals21.84-0.01 (-0.1%)

Acadia Pharmaceuticals will report earnings after the market closes. View Calendar The market is expecting a ±10.5% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±6.9%. View Expected Move (Conf Call: Nov 5 4:30 PM)
Unusual Option Volume

ACAD Acadia Pharmaceuticals20.97-2.63 (-11.1%)

Acadia Pharmaceuticals trades 6,731 contracts. The highest volume is in the 21-Nov-25 26 calls, which is 24.0% above the current price. News: Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
ACAD #AcadiaPharmaceuticals stock declines -11.0% in premarket,

Premarket Decliner

Market Data Delayed 15 Minutes